| NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
| 631 Jämtland |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 43 | 1.0% | 3 | 0.1% | 1 | 0.0% | . | . | . | . | 1 | 0.0% | 4412 | 98.9% | 4460 | 100.0% |
| ASCUS | 93 | 35.9% | 35 | 13.5% | 23 | 8.9% | . | . | . | . | 2 | 0.8% | 106 | 40.9% | 259 | 100.0% |
| LSIL | 30 | 28.6% | 30 | 28.6% | 15 | 14.3% | . | . | . | . | 2 | 1.9% | 28 | 26.7% | 105 | 100.0% |
| Atypical glandular cells/AGC | 5 | 55.6% | 1 | 11.1% | 1 | 11.1% | 2 | 22.2% | . | . | . | . | . | . | 9 | 100.0% |
| Unclear atypia | 2 | 66.7% | . | . | 1 | 33.3% | . | . | . | . | . | . | . | . | 3 | 100.0% |
| ASC-H | 7 | 21.2% | 3 | 9.1% | 19 | 57.6% | 1 | 3.0% | 1 | 3.0% | 1 | 3.0% | 1 | 3.0% | 33 | 100.0% |
| HSIL | 1 | 2.8% | . | . | 32 | 88.9% | 1 | 2.8% | 2 | 5.6% | . | . | . | . | 36 | 100.0% |
| Totalt | 181 | 3.7% | 72 | 1.5% | 92 | 1.9% | 4 | 0.1% | 3 | 0.1% | 6 | 0.1% | 4547 | 92.7% | 4905 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M80703, M81403 |